

Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/BC56886AC28EN.html>

Date: February 2021

Pages: 71

Price: US\$ 125.00 (Single User License)

ID: BC56886AC28EN

Abstracts

Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Biogen Inc (Biogen) is a biopharmaceutical company that discovers, develops and delivers drugs and biosimilars for the treatment of neurological and neurodegenerative diseases. The company's marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets) and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson's disease, Alzheimer's disease and idiopathic pulmonary fibrosis and stroke among others. The company sells its products through direct sales forces, marketing groups and distributors in the Americas, Europe, Asia and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

Biogen Inc Key Recent Developments

Feb 11,2021: Biogen and Labcentral Award two golden tickets to local and innovative science startups

Feb 11,2021: Biogen Announces the Expiration Date Results of Its Private Exchange Offer

Feb 11,2021: Bolden Therapeutics receives Biogen-LabCentral 'Golden Ticket' award

Feb 05,2021: Biogen offers Arcadia's home renewable energy program to employees

Feb 03,2021: Biogen reports fourth quarter and full year 2020 results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

Table of Contents

List of Tables

List of Figures

SECTION 1 - ABOUT THE COMPANY

Biogen Inc - Key Facts

Biogen Inc - Key Employees

Biogen Inc - Key Employee Biographies

Biogen Inc - Major Products and Services

Biogen Inc - History

Biogen Inc - Company Statement

Biogen Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview

Biogen Inc - Business Description

Product Category: Biosimilars

Overview

Performance

Product Category: Multiple Sclerosis

Overview

Performance

Product Category: Others

Overview

Performance

Product Category: Spinal Muscular Atrophy

Overview

Performance

Geographical Segment: Asia

Performance

Geographical Segment: Europe

Performance

Geographical Segment: Other
Performance
Geographical Segment: US
Performance
R&D Overview
Biogen Inc - Corporate Strategy
Biogen Inc - SWOT Analysis
SWOT Analysis - Overview
Biogen Inc - Strengths
Biogen Inc - Weaknesses
Biogen Inc - Opportunities
Biogen Inc - Threats
Biogen Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Biogen Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 11, 2021: Biogen and Labcentral Award two golden tickets to local and innovative science startups
Feb 11, 2021: Biogen Announces the Expiration Date Results of Its Private Exchange Offer
Feb 11, 2021: Bolden Therapeutics receives Biogen-LabCentral ‘Golden Ticket’ award
Feb 05, 2021: Biogen offers Arcadia's home renewable energy program to employees
Feb 03, 2021: Biogen reports fourth quarter and full year 2020 results
Jan 11, 2021: Biogen to launch pioneering study to develop digital biomarkers of

cognitive health using Apple Watch and Iphone

Jan 07, 2021: Sage Therapeutics provides 2021 corporate strategy update at J.P. Morgan Healthcare Conference

Dec 17, 2020: Biogen agrees to pay \$22 million to resolve allegations that it paid kickbacks through two co-pay foundations

Dec 17, 2020: Biogen agrees to pay \$22 million to resolve alleged false claims act liability for paying kickbacks

Dec 08, 2020: UK Biobank unveils studies to measure circulating protein concentrations

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Biogen Inc, Key Facts
Biogen Inc, Key Employees
Biogen Inc, Key Employee Biographies
Biogen Inc, Major Products and Services
Biogen Inc, History
Biogen Inc, Other Locations
Biogen Inc, Subsidiaries
Biogen Inc, Joint Venture
Biogen Inc, Key Competitors
Biogen Inc, Ratios based on current share price
Biogen Inc, Annual Ratios
Biogen Inc, Annual Ratios (Cont...1)
Biogen Inc, Annual Ratios (Cont...2)
Biogen Inc, Interim Ratios
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Biogen Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Biogen Inc, Performance Chart (2016 - 2020)

Biogen Inc, Ratio Charts

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Biogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

COMPANIES MENTIONED

United Neuroscience Ltd

Teva Pharmaceutical Industries Ltd

Sanofi

Principia Biopharma Inc

Pfizer Inc

Novartis AG

Merck & Co Inc

Dart NeuroScience LLC

Bayer HealthCare Pharmaceuticals

Alzheon Inc

I would like to order

Product name: Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/BC56886AC28EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BC56886AC28EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970